The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Year: 2011
Type: review
Abstract: A large fraction of human tumors carry p53 mutations, which allow tumor initiation and progression; furthermore, it is now clear that restoration or reactivation of wild-type p53 function prompts rapid elimination of tumors. The discovery and design of compounds that reactivate or enhance the p53 pathway has resulted in the identification of promising drug candidates that have now entered clinical trials for anticancer strategies. However, some of these agents appear to elicit undesirable toxic effects on normal cells and tissues and therefore are restricted in the dose that can be applied in tumors. In this Review, we discuss the concerns about and promise of these p53 activators and propose ways to expand and optimize screening strategies to identify such molecules.
Source: Science Translational Medicine
Authors: Anna Mandinova, Sam W. Lee
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
Awards: Cell fate decision in response to p53-dependent DNA damage/genotoxic stress, Role of an unusual GTPase in DNA damage response and carcinogenesis, Targeting ROS by a p53-activating agent for selective killing of cancer cells, p53-GAMT pathway in cancer cell metabolism and DNA damage-induced carcinogenesis, p53 - Regulators and Effectors, Role of a novel Notch1 target gene in skin carcinogenesis
OpenAlex ID: W2002091909
